Autoimmune Disease Treatment Market – Opportunity Analysis, 2026

According to National Institute of Health (NIH), there were approximately 23.5 million American’s suffering from an autoimmune disease in 2012. Moreover, Department of Health and Human Services, in 2017, reported that autoimmune disease (AID) is ranked first in the top ten list of popular health topics. Autoimmune disease has a severe impact on a health, which may lead to various complications in different part of the body, such as heart, brain, kidneys, glands, and nerves. Increasing rate of autoimmune disease is mainly due to genetic and environmental factors, which include dietary components, toxic chemical, and infections.

Click To Continue Reading on Autoimmune Disease Treatment Market

Autoimmune diseases include inflammatory bowel diseases (IBD), rheumatic arthritis (RA), multiple sclerosis (MS), celiac disease (CD), hepatitis, autoimmune thyroiditis (AT), systemic lupus erythematous (SLE) and type 1 diabetes (IDDM). According to International Journal of Celiac Disease, in 2015, stated that the environmental factors are strongly related to cause autoimmune diseases, which include infections, ecology, and nutrition.

Diagnosis of AID is challenging due to lack of basic knowledge about disease pattern, to identify treatments, and design clinical trials. Increasing awareness among the population about autoimmune diseases and its complications is expected to contribute towards the growth of autoimmune disease treatment market.

Innovation in the treatment of AID is expected to augment the autoimmune disease treatment market. For instance, researchers at the Perelman School of Medicine in 2016, found a way to target a specific subset of antibody, which is responsible for the activation of pemphigus vulgaris (PV) autoimmune disease. The researchers designed chimeric autoantibody receptor therapy (CAART) that can be used to treat this disease without harming the healthy immune system.

Moreover, researchers at the Cumming School of Medicine in 2016, developed a new class of Nano-medicine to treat diseases, specifically type 1 diabetes, multiple sclerosis, and rheumatoid arthritis without compromising immunity. This Nano-medicine is currently being developed at Parvus Therapeutics, Inc., and is funded by Innovate Calgary.

According to the American Autoimmune Related Diseases Association (AARDA), in 2017, approximately 50 million Americans are suffering from autoimmune disease. High prevalence of autoimmune diseases demands for new treatment approach, which may include biomarkers, stem cell research, and genetic research. Biological agents such as TNF agents, monoclonal antibodies, tissue and organ engineering procedure, gene-based delivery system, modulators of the immune system, and cell-based treatments are under evaluation for the treatment of AID in near future.

Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/895

Key Vendors:

Johnson & Johnson, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Active Biotech, GlaxoSmithKline plc, Eli Lilly and Company, AutoImmune Inc., Pfizer, Inc. AstraZeneca plc, Lupin Limited, 4SC AG, Amgen, Inc., and Bristol-Myers Squibb.